 |
 Video: What is a Stock Split?
|
|
|
| Avadel Pharmaceuticals is a biopharmaceutical company. Co.'s primary product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. Co.'s commercial products are: Akovaz, which is indicated for the treatment of hypotension occurring in the setting of anesthesia; Bloxiverz, which is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep®, which is for the treatment of hypotension occuring in the setting of anesthesia; and Nouress, which is a sterile injectable product for use in the hospital setting. According to our Avadel Pharmaceuticals PLC stock split history records, Avadel Pharmaceuticals PLC has had 0 splits. | |
|
Avadel Pharmaceuticals PLC (AVDL) has 0 splits in our Avadel Pharmaceuticals PLC stock split history database.
Looking at the Avadel Pharmaceuticals PLC stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Avadel Pharmaceuticals PLC shares, starting with a $10,000 purchase of AVDL, presented on a split-history-adjusted basis factoring in the complete Avadel Pharmaceuticals PLC stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/24/2014 |
|
| End date: |
04/22/2024 |
|
| Start price/share: |
$11.80 |
|
| End price/share: |
$17.30 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
46.61% |
|
| Average Annual Total Return: |
3.90% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$14,662.26 |
|
| Years: |
10.00 |
|
|
|
|
|
